Media contact

Medical humanitarian organisation uses ‘Humanitarian Mechanism’ programme to access affordable versions of pneumonia vaccine to protect refugee children in Greece against the number one childhood killer worldwide

Most recent Priority Review Voucher is a reminder of why Congress should reform the US government program to only reward companies for developing new and affordable drugs and vaccines for neglected diseases

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug bedaquiline.

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.

The appeal – filed by six organisations – states that the EPO should revoke Gilead’s patent on key hepatitis C drug sofosbuvir because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.

MSF criticises pharma for dragging feet on developing HIV drugs for children.

As ministers and leaders from member countries gather in Singapore this week, Japan and South Korea continue to push India and the ten member states of ASEAN to agree to IP provisions that undermine generic competition.

MSF calls on Global Fund Board to make urgent changes to prevent drug stock-outs and quality issues.